现代医药卫生2016，Vol.32Issue(9)：1284-1286,1289,4.DOI:10.3969/j.issn.1009-5519.2016.09.002
罗格列酮对初诊为2型糖尿病患者血清SPARC的影响
Effect of rosiglitazone on serum SPARC in patients with newly diagnosed type 2 diabetes mellitus
摘要
Abstract
Objective To investigate the effect of rosiglitazone on the levels of secreted protein acidic and rich in cys teine(SPARC) in the patients with type 2 diabetes mellitus(T2DM). Methods Seventy-eight patients with newly diagnosed T2DM in our hospital from March 1,2013 to February 28,2014 were included and randomly divided into the rosiglitazone treatment group(40 cases) and exercise diet control group(38 cases). Contemporaneous 53 age-matched individuals undergoing the healthy physical examination were selected as the healthy control group. The treatment group was treated with rosiglitazone 4mg once daily for 16 weeks;the exercise diet control group was conducted the 16-week life style intervention by referring to the Chinese Type 2 Diabetes Prevention and Control Guide(version 2010). The body weight,BMI,blood lipid and insulin resistance related indexes in various groups were compared before and after intervention. Serum SPARC level was assayed by ELISA and its changes were compared between before and after treatment. Results The serum level of SPARC before treatment in the treatment group and the exercise diet control group were significantly higher than that in the healthy control group,the difference was statistically signifi-cant (P<0.05). The serum level of SPARC after treatment in the rosiglitazone treatment group and exercise diet control group was decreased with statistical difference(P<0.05),but the decrease amplitude had no statistical difference between the rosiglitazone group and the exercise diet control group(P>0.05). Conclusion The level of fasting serum SPARC in the patients with T2DM is in-creased compared with healthy persons. Rosiglitazone reduces serum SPARC level and its effect is equivalent to diet and exercise therapy.关键词
骨结合素/噻唑烷二酮类/降血糖药/糖尿病,2型/半胱氨酸/代谢/胰岛素敏感性/罗格列酮Key words
Osteonectin/Thiazolidinediones/Hypoglycemic agents/Diabetes mellitus,type 2/Cysteine/metabolism/Insulin sensitivity/Rosiglitazone引用本文复制引用
黄丹,魏晓,李志勇,瞿文娟,王成潘,陈燕梅,陈德智..罗格列酮对初诊为2型糖尿病患者血清SPARC的影响[J].现代医药卫生,2016,32(9):1284-1286,1289,4.基金项目
重庆市卫生局医学科研计划项目（2011-2-286、2012-2-155）。 （）
